A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism

A. Dhanushkodi, E. O. Akano, E. E. Roguski, Y. Xue, S. K. Rao, S. G. Matta, T. S. Rex, M. P. Mcdonald

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Erythropoietin (Epo) is neuroprotective in a number of preparations, but can lead to unacceptably high and even lethal hematocrit levels. Recent reports show that modified Epo variants confer neuroprotection in models of glaucoma and retinal degeneration without raising hematocrit. In this study, neuroprotective effects of two Epo variants (EpoR76E and EpoS71E) were assessed in a model of Parkinson's disease. The constructs were packaged in recombinant adeno-associated viral (rAAV) vectors and injected intramuscularly. After 3weeks, mice received five daily injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and were killed 5weeks later. The MPTP-lesioned mice pretreated with rAAV.eGFP (negative control) exhibited a 7- to 9-Hz tremor and slower latencies to move on a grid test (akinesia). Both of these symptomatic features were absent in mice pretreated with either modified Epo construct. The rAAV.eGFP-treated mice lesioned with MPTP exhibited a 41% reduction in tyrosine hydroxylase (TH)-positive neurons in the substantia nigra. The rAAV.EpoS71E construct did not protect nigral neurons, but neuronal loss in mice pretreated with rAAV.EpoR76E was only half that of rAAV.eGFP controls. Although dopamine levels were normal in all groups, 3,4-dihydroxyphenylacetic acid (DOPAC) was significantly reduced only in MPTP-lesioned mice pretreated with rAAV.eGFP, indicating reduced dopamine turnover. Analysis of TH-positive fibers in the striatum showed normalized density in MPTP-lesioned mice pretreated with rAAV.EpoS71E, suggesting that enhanced sprouting induced by EpoS71E may have been responsible for normal behavior and dopaminergic tone in these mice. These results show that systemically administered rAAV-generated non-erythropoietic Epo may protect against MPTP-induced parkinsonism by a combination of neuroprotection and enhanced axonal sprouting. A single injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced dopaminergic cell death.

Original languageEnglish
Pages (from-to)224-233
Number of pages10
JournalGenes, Brain and Behavior
Volume12
Issue number2
DOIs
Publication statusPublished - 03-2013

Fingerprint

Intramuscular Injections
Parkinsonian Disorders
Erythropoietin
Tyrosine 3-Monooxygenase
Substantia Nigra
Hematocrit
Dopamine
Neurons
3,4-Dihydroxyphenylacetic Acid
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Retinal Degeneration
Injections
4-phenyl-1,2,3,6-tetrahydropyridine
Neuroprotective Agents
Tremor
Glaucoma
Parkinson Disease
Cell Death

All Science Journal Classification (ASJC) codes

  • Behavioral Neuroscience
  • Genetics
  • Neurology

Cite this

Dhanushkodi, A. ; Akano, E. O. ; Roguski, E. E. ; Xue, Y. ; Rao, S. K. ; Matta, S. G. ; Rex, T. S. ; Mcdonald, M. P. / A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism. In: Genes, Brain and Behavior. 2013 ; Vol. 12, No. 2. pp. 224-233.
@article{550a6fac159748d49819b2ccbc7337e6,
title = "A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism",
abstract = "Erythropoietin (Epo) is neuroprotective in a number of preparations, but can lead to unacceptably high and even lethal hematocrit levels. Recent reports show that modified Epo variants confer neuroprotection in models of glaucoma and retinal degeneration without raising hematocrit. In this study, neuroprotective effects of two Epo variants (EpoR76E and EpoS71E) were assessed in a model of Parkinson's disease. The constructs were packaged in recombinant adeno-associated viral (rAAV) vectors and injected intramuscularly. After 3weeks, mice received five daily injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and were killed 5weeks later. The MPTP-lesioned mice pretreated with rAAV.eGFP (negative control) exhibited a 7- to 9-Hz tremor and slower latencies to move on a grid test (akinesia). Both of these symptomatic features were absent in mice pretreated with either modified Epo construct. The rAAV.eGFP-treated mice lesioned with MPTP exhibited a 41{\%} reduction in tyrosine hydroxylase (TH)-positive neurons in the substantia nigra. The rAAV.EpoS71E construct did not protect nigral neurons, but neuronal loss in mice pretreated with rAAV.EpoR76E was only half that of rAAV.eGFP controls. Although dopamine levels were normal in all groups, 3,4-dihydroxyphenylacetic acid (DOPAC) was significantly reduced only in MPTP-lesioned mice pretreated with rAAV.eGFP, indicating reduced dopamine turnover. Analysis of TH-positive fibers in the striatum showed normalized density in MPTP-lesioned mice pretreated with rAAV.EpoS71E, suggesting that enhanced sprouting induced by EpoS71E may have been responsible for normal behavior and dopaminergic tone in these mice. These results show that systemically administered rAAV-generated non-erythropoietic Epo may protect against MPTP-induced parkinsonism by a combination of neuroprotection and enhanced axonal sprouting. A single injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced dopaminergic cell death.",
author = "A. Dhanushkodi and Akano, {E. O.} and Roguski, {E. E.} and Y. Xue and Rao, {S. K.} and Matta, {S. G.} and Rex, {T. S.} and Mcdonald, {M. P.}",
year = "2013",
month = "3",
doi = "10.1111/gbb.12001",
language = "English",
volume = "12",
pages = "224--233",
journal = "Genes, Brain and Behavior",
issn = "1601-1848",
publisher = "Wiley-Blackwell",
number = "2",

}

A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism. / Dhanushkodi, A.; Akano, E. O.; Roguski, E. E.; Xue, Y.; Rao, S. K.; Matta, S. G.; Rex, T. S.; Mcdonald, M. P.

In: Genes, Brain and Behavior, Vol. 12, No. 2, 03.2013, p. 224-233.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism

AU - Dhanushkodi, A.

AU - Akano, E. O.

AU - Roguski, E. E.

AU - Xue, Y.

AU - Rao, S. K.

AU - Matta, S. G.

AU - Rex, T. S.

AU - Mcdonald, M. P.

PY - 2013/3

Y1 - 2013/3

N2 - Erythropoietin (Epo) is neuroprotective in a number of preparations, but can lead to unacceptably high and even lethal hematocrit levels. Recent reports show that modified Epo variants confer neuroprotection in models of glaucoma and retinal degeneration without raising hematocrit. In this study, neuroprotective effects of two Epo variants (EpoR76E and EpoS71E) were assessed in a model of Parkinson's disease. The constructs were packaged in recombinant adeno-associated viral (rAAV) vectors and injected intramuscularly. After 3weeks, mice received five daily injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and were killed 5weeks later. The MPTP-lesioned mice pretreated with rAAV.eGFP (negative control) exhibited a 7- to 9-Hz tremor and slower latencies to move on a grid test (akinesia). Both of these symptomatic features were absent in mice pretreated with either modified Epo construct. The rAAV.eGFP-treated mice lesioned with MPTP exhibited a 41% reduction in tyrosine hydroxylase (TH)-positive neurons in the substantia nigra. The rAAV.EpoS71E construct did not protect nigral neurons, but neuronal loss in mice pretreated with rAAV.EpoR76E was only half that of rAAV.eGFP controls. Although dopamine levels were normal in all groups, 3,4-dihydroxyphenylacetic acid (DOPAC) was significantly reduced only in MPTP-lesioned mice pretreated with rAAV.eGFP, indicating reduced dopamine turnover. Analysis of TH-positive fibers in the striatum showed normalized density in MPTP-lesioned mice pretreated with rAAV.EpoS71E, suggesting that enhanced sprouting induced by EpoS71E may have been responsible for normal behavior and dopaminergic tone in these mice. These results show that systemically administered rAAV-generated non-erythropoietic Epo may protect against MPTP-induced parkinsonism by a combination of neuroprotection and enhanced axonal sprouting. A single injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced dopaminergic cell death.

AB - Erythropoietin (Epo) is neuroprotective in a number of preparations, but can lead to unacceptably high and even lethal hematocrit levels. Recent reports show that modified Epo variants confer neuroprotection in models of glaucoma and retinal degeneration without raising hematocrit. In this study, neuroprotective effects of two Epo variants (EpoR76E and EpoS71E) were assessed in a model of Parkinson's disease. The constructs were packaged in recombinant adeno-associated viral (rAAV) vectors and injected intramuscularly. After 3weeks, mice received five daily injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and were killed 5weeks later. The MPTP-lesioned mice pretreated with rAAV.eGFP (negative control) exhibited a 7- to 9-Hz tremor and slower latencies to move on a grid test (akinesia). Both of these symptomatic features were absent in mice pretreated with either modified Epo construct. The rAAV.eGFP-treated mice lesioned with MPTP exhibited a 41% reduction in tyrosine hydroxylase (TH)-positive neurons in the substantia nigra. The rAAV.EpoS71E construct did not protect nigral neurons, but neuronal loss in mice pretreated with rAAV.EpoR76E was only half that of rAAV.eGFP controls. Although dopamine levels were normal in all groups, 3,4-dihydroxyphenylacetic acid (DOPAC) was significantly reduced only in MPTP-lesioned mice pretreated with rAAV.eGFP, indicating reduced dopamine turnover. Analysis of TH-positive fibers in the striatum showed normalized density in MPTP-lesioned mice pretreated with rAAV.EpoS71E, suggesting that enhanced sprouting induced by EpoS71E may have been responsible for normal behavior and dopaminergic tone in these mice. These results show that systemically administered rAAV-generated non-erythropoietic Epo may protect against MPTP-induced parkinsonism by a combination of neuroprotection and enhanced axonal sprouting. A single injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced dopaminergic cell death.

UR - http://www.scopus.com/inward/record.url?scp=84874189407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874189407&partnerID=8YFLogxK

U2 - 10.1111/gbb.12001

DO - 10.1111/gbb.12001

M3 - Article

VL - 12

SP - 224

EP - 233

JO - Genes, Brain and Behavior

JF - Genes, Brain and Behavior

SN - 1601-1848

IS - 2

ER -